Merck and Moderna said on Wednesday a study of a personalized mRNA vaccine combined ​with the immunotherapy drug Keytruda reduced melanoma skin ‌cancer recurrence and spread compared with Keytruda alone, the first positive late-stage trial results for an mRNA cancer vaccine.